StockMarketWire.com - Indivior warned Wednesday that net revenue and net income would fall short of previous guidance, as the launch of generic versions of its opioid addiction treatment in the United States would weigh on performance.

The profit warning came after Dr.Reddy’s Laboratories and U.S.-based Mylan NV received approval from the Food and Drug Administration in June to launch a generic version of Indivior’s Suboxone Film.

The company previously guided for 2018 net revenue in the range of $1.13bn to $1.17bn and adjusted net income of $280m to $320m. Story provided by StockMarketWire.com